Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Insulet (PODD)

NASDAQ: PODD · Medical Devices · Acton, MA

Our rating: Positive

Positive reaffirmed at $156.12, moderate conviction, November 5, 2026.

Breaks if: The Positive call is wrong if revenue growth in either of the next two quarterly filings comes in below 18% year-over-year — that would signal the 30%-plus run rate is breaking down structurally rather than moderating gradually. It also turns Cautious if reported net margin falls below 7% over the same two-quarter window, implying operating leverage is running in reverse at scale. Neither condition is met today.

Key figures

Market value$9.2B
Revenue, last 12 months$3.2B
Net income, last 12 months$429M
Free cash flow, last 12 months$260M
Price to earnings21.5×
Free cash flow yield2.8%
Dividend yield0.0%
Operating margin18.4%
Return on equity28.9%
Beta to the S&P 5000.69
Volatility, annualized41.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$842M19.2%$2.03$66M
June 30, 2026$802M23.5%$1.37$56M
March 31, 2026$762M33.9%$1.30$90M
December 31, 2025$784M31.2%$1.43$48M
September 30, 2025$706M29.9%$1.24$100M
June 30, 2025$649M32.9%$0.32$178M
March 31, 2025$569M28.8%$0.50$52M
December 31, 2024$598M17.2%$1.38$94M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

12 ledger entries and 66 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.